Date: 2012-05-08
Type of information: R&D agreement
Compound: genetic tests in cardiovascular, metabolic and neurological diseases
Company: Multiplicom (Belgium) ICAN (France) ICM (France)
Therapeutic area: Cardiovascular diseases - Metabolic diseases - Neurological diseases
Type agreement: R&D
Action mechanism:
Disease: cardiovascular, metabolic (diabetes...) and neurological diseases
Details: Multiplicom, a Belgian diagnostics company, specialized in the design, development, production, and commercialization of innovative molecular genetic tests based on massive parallel sequencing, has established research collaborations with two French two Hospital-University Institutes (IHU), ICAN and ICM, focused on development of genetic tests in cardiovascular, metabolic and neurological diseases Multiplicom will be responsible for the commercialization of the resulting products. As a first project an early onset diabetes test will be developed, with additional projects following shortly thereafter.
The partners will jointly develop a new generation of molecular diagnostic tests to identify disease predisposition mutations in cardiovascular, metabolic and neurological diseases. Multiplicom’s expertise in the development of massive parallel sequencing based molecular diagnostics in combination with the disease specific knowledge and the availability of well documented samples at ICAN and ICM will lead to the development of innovative diagnostic tests that will help patients and their doctors to prevent and/or cure disease in an early stage.
Financial terms:
Latest news:
